CN1652815A - 针对流感病毒m2蛋白的人单克隆抗体其制备和使用方法 - Google Patents
针对流感病毒m2蛋白的人单克隆抗体其制备和使用方法 Download PDFInfo
- Publication number
- CN1652815A CN1652815A CNA03810797XA CN03810797A CN1652815A CN 1652815 A CN1652815 A CN 1652815A CN A03810797X A CNA03810797X A CN A03810797XA CN 03810797 A CN03810797 A CN 03810797A CN 1652815 A CN1652815 A CN 1652815A
- Authority
- CN
- China
- Prior art keywords
- antibody
- atcc
- preserving number
- usa
- manassas
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010022000 influenza Diseases 0.000 title claims abstract description 103
- 241000282414 Homo sapiens Species 0.000 title claims abstract description 36
- 238000000034 method Methods 0.000 title claims description 92
- 101001039853 Sonchus yellow net virus Matrix protein Proteins 0.000 title abstract description 5
- 241000712461 unidentified influenza virus Species 0.000 claims abstract description 103
- 238000011282 treatment Methods 0.000 claims abstract description 34
- 210000004027 cell Anatomy 0.000 claims description 119
- 241000700605 Viruses Species 0.000 claims description 87
- 230000027455 binding Effects 0.000 claims description 75
- 210000004408 hybridoma Anatomy 0.000 claims description 39
- 150000007523 nucleic acids Chemical class 0.000 claims description 37
- 235000001014 amino acid Nutrition 0.000 claims description 35
- 150000001413 amino acids Chemical class 0.000 claims description 35
- 102000039446 nucleic acids Human genes 0.000 claims description 35
- 108020004707 nucleic acids Proteins 0.000 claims description 35
- 101100230376 Acetivibrio thermocellus (strain ATCC 27405 / DSM 1237 / JCM 9322 / NBRC 103400 / NCIMB 10682 / NRRL B-4536 / VPI 7372) celI gene Proteins 0.000 claims description 33
- 241000699802 Cricetulus griseus Species 0.000 claims description 33
- 210000001672 ovary Anatomy 0.000 claims description 33
- 108090000623 proteins and genes Proteins 0.000 claims description 32
- 208000024891 symptom Diseases 0.000 claims description 31
- 238000012360 testing method Methods 0.000 claims description 31
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 26
- 230000009385 viral infection Effects 0.000 claims description 26
- 208000015181 infectious disease Diseases 0.000 claims description 23
- 241001465754 Metazoa Species 0.000 claims description 22
- 235000018102 proteins Nutrition 0.000 claims description 22
- 102000004169 proteins and genes Human genes 0.000 claims description 22
- 238000002965 ELISA Methods 0.000 claims description 21
- 208000036142 Viral infection Diseases 0.000 claims description 21
- 230000001225 therapeutic effect Effects 0.000 claims description 20
- 125000003729 nucleotide group Chemical group 0.000 claims description 17
- 239000002773 nucleotide Substances 0.000 claims description 16
- 239000003443 antiviral agent Substances 0.000 claims description 12
- 210000003695 paranasal sinus Anatomy 0.000 claims description 12
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 11
- 210000004072 lung Anatomy 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 206010011224 Cough Diseases 0.000 claims description 10
- 206010049119 Emotional distress Diseases 0.000 claims description 10
- 206010019233 Headaches Diseases 0.000 claims description 10
- 206010028735 Nasal congestion Diseases 0.000 claims description 10
- 206010068319 Oropharyngeal pain Diseases 0.000 claims description 10
- 208000005141 Otitis Diseases 0.000 claims description 10
- 206010035664 Pneumonia Diseases 0.000 claims description 10
- 206010006451 bronchitis Diseases 0.000 claims description 10
- 230000034994 death Effects 0.000 claims description 10
- 230000009429 distress Effects 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 208000019258 ear infection Diseases 0.000 claims description 10
- 231100000869 headache Toxicity 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 210000001331 nose Anatomy 0.000 claims description 10
- 201000009890 sinusitis Diseases 0.000 claims description 10
- 208000023409 throat pain Diseases 0.000 claims description 10
- 230000029812 viral genome replication Effects 0.000 claims description 10
- 206010014020 Ear pain Diseases 0.000 claims description 9
- 241000196324 Embryophyta Species 0.000 claims description 9
- 208000027744 congestion Diseases 0.000 claims description 9
- 208000007176 earache Diseases 0.000 claims description 9
- 238000010438 heat treatment Methods 0.000 claims description 9
- 206010016256 fatigue Diseases 0.000 claims description 8
- 238000002372 labelling Methods 0.000 claims description 8
- 230000008034 disappearance Effects 0.000 claims description 7
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 230000000844 anti-bacterial effect Effects 0.000 claims description 5
- 230000002255 enzymatic effect Effects 0.000 claims description 5
- 210000004400 mucous membrane Anatomy 0.000 claims description 5
- 239000000443 aerosol Substances 0.000 claims description 3
- 210000000867 larynx Anatomy 0.000 claims description 3
- 210000003800 pharynx Anatomy 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 230000001588 bifunctional effect Effects 0.000 claims description 2
- 239000002955 immunomodulating agent Substances 0.000 claims description 2
- 230000002584 immunomodulator Effects 0.000 claims description 2
- 229940121354 immunomodulator Drugs 0.000 claims description 2
- 239000003053 toxin Substances 0.000 claims description 2
- 231100000765 toxin Toxicity 0.000 claims description 2
- 230000009261 transgenic effect Effects 0.000 claims description 2
- 230000002238 attenuated effect Effects 0.000 claims 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 230000001524 infective effect Effects 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 description 57
- 108020004414 DNA Proteins 0.000 description 50
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 44
- 108090000765 processed proteins & peptides Proteins 0.000 description 41
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 38
- 230000000694 effects Effects 0.000 description 37
- 102000053602 DNA Human genes 0.000 description 35
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 31
- 230000014509 gene expression Effects 0.000 description 28
- 238000000746 purification Methods 0.000 description 27
- 239000000203 mixture Substances 0.000 description 26
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 23
- 239000012634 fragment Substances 0.000 description 22
- 239000000523 sample Substances 0.000 description 18
- 238000011534 incubation Methods 0.000 description 17
- 238000002360 preparation method Methods 0.000 description 17
- 108060003951 Immunoglobulin Proteins 0.000 description 16
- 102000018358 immunoglobulin Human genes 0.000 description 16
- 239000013612 plasmid Substances 0.000 description 16
- 239000013598 vector Substances 0.000 description 15
- 239000000427 antigen Substances 0.000 description 13
- 102000036639 antigens Human genes 0.000 description 13
- 108091007433 antigens Proteins 0.000 description 13
- 239000013604 expression vector Substances 0.000 description 13
- 238000005516 engineering process Methods 0.000 description 12
- 230000008859 change Effects 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 238000005406 washing Methods 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 239000002299 complementary DNA Substances 0.000 description 10
- 108700010900 influenza virus proteins Proteins 0.000 description 10
- 238000001514 detection method Methods 0.000 description 9
- 230000036039 immunity Effects 0.000 description 9
- 230000002265 prevention Effects 0.000 description 9
- 230000004083 survival effect Effects 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 125000000539 amino acid group Chemical group 0.000 description 8
- 230000008878 coupling Effects 0.000 description 8
- 238000010168 coupling process Methods 0.000 description 8
- 238000005859 coupling reaction Methods 0.000 description 8
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 230000001681 protective effect Effects 0.000 description 8
- 229920002477 rna polymer Polymers 0.000 description 8
- 230000000670 limiting effect Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 101710154606 Hemagglutinin Proteins 0.000 description 6
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 6
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 6
- 101710176177 Protein A56 Proteins 0.000 description 6
- 229920002684 Sepharose Polymers 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000006062 fragmentation reaction Methods 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 239000000185 hemagglutinin Substances 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 208000037797 influenza A Diseases 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000003752 polymerase chain reaction Methods 0.000 description 6
- 102000040430 polynucleotide Human genes 0.000 description 6
- 108091033319 polynucleotide Proteins 0.000 description 6
- 239000002157 polynucleotide Substances 0.000 description 6
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 238000004520 electroporation Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 230000002085 persistent effect Effects 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 229960005486 vaccine Drugs 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 4
- 241000283707 Capra Species 0.000 description 4
- 238000012449 Kunming mouse Methods 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 238000000246 agarose gel electrophoresis Methods 0.000 description 4
- 238000011091 antibody purification Methods 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000013467 fragmentation Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 230000009545 invasion Effects 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 238000005497 microtitration Methods 0.000 description 4
- 201000000050 myeloid neoplasm Diseases 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 239000005022 packaging material Substances 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 230000009257 reactivity Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 230000009870 specific binding Effects 0.000 description 4
- 210000004988 splenocyte Anatomy 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 241000701822 Bovine papillomavirus Species 0.000 description 3
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 3
- 108091035707 Consensus sequence Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000008214 Glutamate decarboxylase Human genes 0.000 description 3
- 108091022930 Glutamate decarboxylase Proteins 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 206010061598 Immunodeficiency Diseases 0.000 description 3
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 3
- 102000005348 Neuraminidase Human genes 0.000 description 3
- 108010006232 Neuraminidase Proteins 0.000 description 3
- 108010038807 Oligopeptides Proteins 0.000 description 3
- 102000015636 Oligopeptides Human genes 0.000 description 3
- 102100021079 Ornithine decarboxylase Human genes 0.000 description 3
- 102000057297 Pepsin A Human genes 0.000 description 3
- 108090000284 Pepsin A Proteins 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 108091081024 Start codon Proteins 0.000 description 3
- 241000723873 Tobacco mosaic virus Species 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000008676 import Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 229940111202 pepsin Drugs 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000002510 pyrogen Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- YFDSDPIBEUFTMI-UHFFFAOYSA-N tribromoethanol Chemical compound OCC(Br)(Br)Br YFDSDPIBEUFTMI-UHFFFAOYSA-N 0.000 description 3
- 229950004616 tribromoethanol Drugs 0.000 description 3
- -1 venous transfusion Substances 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 2
- 108010026624 GTCGAC-specific type II deoxyribonucleases Proteins 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 101000777550 Homo sapiens CCN family member 2 Proteins 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 239000012480 LAL reagent Substances 0.000 description 2
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000003975 animal breeding Methods 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 230000027645 antigenic variation Effects 0.000 description 2
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 238000005336 cracking Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000030609 dephosphorylation Effects 0.000 description 2
- 238000006209 dephosphorylation reaction Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- VLCYCQAOQCDTCN-UHFFFAOYSA-N eflornithine Chemical compound NCCCC(N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-UHFFFAOYSA-N 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000013230 female C57BL/6J mice Methods 0.000 description 2
- 238000012239 gene modification Methods 0.000 description 2
- 230000005017 genetic modification Effects 0.000 description 2
- 235000013617 genetically modified food Nutrition 0.000 description 2
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 102000047612 human CCN2 Human genes 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 229960001614 levamisole Drugs 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229920002704 polyhistidine Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000008521 reorganization Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012448 transchromosomic mouse model Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- 102100029457 Adenine phosphoribosyltransferase Human genes 0.000 description 1
- 108010024223 Adenine phosphoribosyltransferase Proteins 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- VWEWCZSUWOEEFM-WDSKDSINSA-N Ala-Gly-Ala-Gly Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(O)=O VWEWCZSUWOEEFM-WDSKDSINSA-N 0.000 description 1
- 241000024188 Andala Species 0.000 description 1
- 208000031873 Animal Disease Models Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000345998 Calamus manan Species 0.000 description 1
- 241000701489 Cauliflower mosaic virus Species 0.000 description 1
- 241000759568 Corixa Species 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 230000007023 DNA restriction-modification system Effects 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 101000595467 Homo sapiens T-complex protein 1 subunit gamma Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 241000282620 Hylobates sp. Species 0.000 description 1
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical class C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 101100261636 Methanothermobacter marburgensis (strain ATCC BAA-927 / DSM 2133 / JCM 14651 / NBRC 100331 / OCM 82 / Marburg) trpB2 gene Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 229940122060 Ornithine decarboxylase inhibitor Drugs 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 206010034016 Paronychia Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 241000711904 Pneumoviridae Species 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 239000012564 Q sepharose fast flow resin Substances 0.000 description 1
- 238000012181 QIAquick gel extraction kit Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 102100036049 T-complex protein 1 subunit gamma Human genes 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 241001504501 Troglodytes Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- UPEZCKBFRMILAV-UHFFFAOYSA-N alpha-Ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C(O)CCC(C)(C)O)C)CCC33O)C)C3=CC(=O)C21 UPEZCKBFRMILAV-UHFFFAOYSA-N 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 238000012197 amplification kit Methods 0.000 description 1
- 238000011558 animal model by disease Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000002986 anti-lethal effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 102220369446 c.1274G>A Human genes 0.000 description 1
- 102220369445 c.668T>C Human genes 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000011111 cardboard Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-M cholate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-M 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-M fusidate Chemical class O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C([O-])=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-M 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 101150106093 gpt gene Proteins 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000010231 histologic analysis Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000012516 mab select resin Substances 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012900 molecular simulation Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000002818 ornithine decarboxylase inhibitor Substances 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 239000011087 paperboard Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 235000012950 rattan cane Nutrition 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 102220023258 rs387907548 Human genes 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Natural products CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 101150081616 trpB gene Proteins 0.000 description 1
- 101150111232 trpB-1 gene Proteins 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
Abstract
Description
编号 | 名称 | 序列5’→3’ | 长度 |
13 | IgG1 | TCTTGTCCACCTTGGTGTGGGCTTGTG | 31-聚体 |
14 | hk-2 | GTTGAAGCTCTTTGTGACGGGCGAGC | 26-聚体 |
15 | hh-4 | GGTGCCAGGGGGAAGACCGATGG | 23-聚体 |
16 | hk-5 | AGGCACACAACAGAGGCAGTTCCAGATTTC | 30-聚体 |
17 | hh-6 | GGTCCGGGAGATCATGAGGGTGTCCTT | 27-聚体 |
18 | SP6 | GATTTAGGTGACACTATAG | 19-聚体 |
19 | T7 | TAATACGACTCACTATAGGG | 20-聚体 |
20 | M240L5BGL | AGAGAGAGAGATCTCTCACCATGAGGGTCCTCGCTCAGCTCCTG | 44-聚体 |
21 | M240L3BSI | CTCTCTCTCGTACGTTTGATCTCCACCTTGGTCC | 34-聚体 |
22 | M240H5SAL | AGAGAGAGGTCGACACCATGAAGCACCTGTGGTTCTTCCT | 40-聚体 |
23 | M240H3NHE | CTCTCTCTGCTAGCTGAGGAGACGGTGACCAGG | 33-聚体 |
24 | SEQU1783 | GGTACGTGAACCGTCAGATCGCCTGGA | 27-聚体 |
25 | SEQU4618 | TCTATATAAGCAGAGCTGGTACGTCC | 27-聚体 |
26 | hh-1 | CCAAGGGCCCATCGGTCTTCCCCCTGGCAC | 30-聚体 |
27 | CMVH903F | GACACCCTCATGATCTCCCGGACC | 24-聚体 |
28 | CMVHF1283 | CGACATCGCCGTGGAGTGGGAGAG | 24-聚体 |
29 | CMVHR1303 | TGTTCTCCGGCTGCCCATTGCTCT | 24-聚体 |
30 | hk-1 | TGGCTGCACCATCTGTCTTCATCTTC | 26-1聚体 |
mAbs | 同种型 轻链 | M2肽* | 感染细胞上的M2** | BAS | OVA | KLH | mGAD*** |
C40C40G1L17L30L40L66N547S212S80S900F1F2 | IgG4 KappaIgG1 KappaIgG2 LambdaIgG2 LambdaIgG3 LambdaIgG1 LambdaIgG1 LambdaIgG1 LambdaIgG1 LambdaIgG1 LambdaIgG1 KappaIgG1 Kappa | +1+++++++++++ | ++++++++++++ | -2----------- | ------------ | ------------ | ------------ |
MAbs* | A/PR/8/34 | M2 | OD450 |
2074 | -++ | --+ | 0.0510.9040.142 |
N547 | -++ | --+ | 0.0650.5040.062 |
L66 | -++ | --+ | 0.0510.9310.113 |
C40G1 | -++ | --+ | 0.0510.7990.195 |
mAbs | Abs*与由以下成分感染的MDCK细胞上的M2的EC50(μg/ml) | |
A/PR/8/34 | A/HK/8/68 | |
2074C40G1C40G4S212S80S900N547L17L30L66F1F2 | 0.08910.18260.30070.50010.21760.20630.10420.15110.17470.1169>10**>10** | 0.18730.09710.8414>10**>10**>10**0.46610.59683.49140.2289>10**>10** |
mAbs | M2* | M2TGE | M2EG | M2TSG | M2 | M2SG | M2P | M2FG |
2074C40C40G1C66N547 | +1++++ | +++++ | +++++ | +++++ | +++++ | +++++ | -2++-+ | +++-+ |
Claims (82)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36499702P | 2002-03-13 | 2002-03-13 | |
US60/364,997 | 2002-03-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1652815A true CN1652815A (zh) | 2005-08-10 |
Family
ID=28041999
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA03810797XA Pending CN1652815A (zh) | 2002-03-13 | 2003-03-13 | 针对流感病毒m2蛋白的人单克隆抗体其制备和使用方法 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20030219442A1 (zh) |
EP (1) | EP1490099A4 (zh) |
JP (1) | JP2005519619A (zh) |
KR (1) | KR20040111402A (zh) |
CN (1) | CN1652815A (zh) |
AU (1) | AU2003223285A1 (zh) |
CA (1) | CA2478973A1 (zh) |
TW (1) | TW200407161A (zh) |
WO (1) | WO2003078600A2 (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101881770A (zh) * | 2009-05-08 | 2010-11-10 | 青岛农业大学 | 猪圆环病毒2型胶体金抗体快速检测试纸条的制备方法 |
CN102238963A (zh) * | 2008-12-04 | 2011-11-09 | 英特塞尔股份公司 | 完全人源性流感m2特异性抗体 |
CN105934443A (zh) * | 2014-01-27 | 2016-09-07 | 豪夫迈·罗氏有限公司 | 抗h7病毒抗体治疗h7n9流感 |
CN106715700A (zh) * | 2014-01-10 | 2017-05-24 | 艾乐美生物科技有限公司 | 能产生比小鼠IgE量高出许多的人源化IgE的基因转殖动物 |
CN112961237A (zh) * | 2021-03-10 | 2021-06-15 | 中国计量科学研究院 | 人源化IgM单克隆抗体标准物质及制备方法 |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2295465B1 (en) * | 2004-12-06 | 2013-02-13 | Kyowa Hakko Kirin Co., Ltd. | Human monoclonal antibodies to influenza M2 protein and methods of making and using same |
GB0522460D0 (en) * | 2005-11-03 | 2005-12-14 | Prendergast Patrick T | Composition and method for the treatment of avian influenza |
AU2007249160B2 (en) * | 2006-05-15 | 2013-09-12 | I2 Pharmaceuticals, Inc. | Neutralizing antibodies to influenza viruses |
US8148085B2 (en) | 2006-05-15 | 2012-04-03 | Sea Lane Biotechnologies, Llc | Donor specific antibody libraries |
US20090098527A1 (en) * | 2006-09-12 | 2009-04-16 | Fischer Gerald W | Biological organism identification product and methods |
US8652782B2 (en) | 2006-09-12 | 2014-02-18 | Longhorn Vaccines & Diagnostics, Llc | Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids |
US8080645B2 (en) | 2007-10-01 | 2011-12-20 | Longhorn Vaccines & Diagnostics Llc | Biological specimen collection/transport compositions and methods |
US8097419B2 (en) | 2006-09-12 | 2012-01-17 | Longhorn Vaccines & Diagnostics Llc | Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009 |
US9481912B2 (en) | 2006-09-12 | 2016-11-01 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and identifying nucleic acid sequences in biological samples |
CN102046654A (zh) * | 2007-03-13 | 2011-05-04 | 胡马斯有限公司 | 针对甲型流感病毒h5n1株系的抗体 |
US9683256B2 (en) | 2007-10-01 | 2017-06-20 | Longhorn Vaccines And Diagnostics, Llc | Biological specimen collection and transport system |
US11041215B2 (en) | 2007-08-24 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | PCR ready compositions and methods for detecting and identifying nucleic acid sequences |
US10004799B2 (en) | 2007-08-27 | 2018-06-26 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
CA2697373C (en) | 2007-08-27 | 2019-05-21 | Longhorn Vaccines & Diagnostics, Llc | Immunogenic compositions and methods |
US11041216B2 (en) | 2007-10-01 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples |
ES2552858T3 (es) | 2007-10-01 | 2015-12-02 | Longhorn Vaccines And Diagnostics, Llc | Recogida de muestras biológicas y sistema de transporte y métodos de uso |
US20110033476A1 (en) * | 2007-11-12 | 2011-02-10 | Theraclone Sciences Inc. | Compositions and methods for the therapy and diagnosis of influenza |
DK2220116T3 (da) | 2007-11-12 | 2012-11-26 | Theraclone Sciences Inc | Sammensætninger og fremgangsmåder til terapien og diagnosticeringen af influenza |
EP2065398A1 (en) | 2007-11-29 | 2009-06-03 | Cytos Biotechnology AG | Human monoclonal nicotine specific antibodies |
TWI473621B (zh) * | 2008-11-12 | 2015-02-21 | Theraclone Sciences Inc | 供治療和診斷流感用之組成物和方法 |
WO2010110737A1 (en) * | 2009-03-23 | 2010-09-30 | Temasek Life Sciences Laboratory Limited | Monoclonal antibody against a conserved domain of m2e polypeptide in influenza viruses |
US8858948B2 (en) | 2009-05-20 | 2014-10-14 | Theraclone Sciences, Inc. | Compositions and methods for the therapy and diagnosis of influenza |
JP5820800B2 (ja) | 2010-03-02 | 2015-11-24 | 協和発酵キリン株式会社 | 改変抗体組成物 |
CN104203272A (zh) | 2012-01-26 | 2014-12-10 | 长角牛疫苗和诊断有限责任公司 | 复合抗原序列及疫苗 |
US9976136B2 (en) | 2015-05-14 | 2018-05-22 | Longhorn Vaccines And Diagnostics, Llc | Rapid methods for the extraction of nucleic acids from biological samples |
CN106478816B (zh) * | 2016-12-12 | 2019-08-16 | 青岛蔚蓝生物制品有限公司 | 一种抗禽流感h9n2病毒的单链抗体 |
WO2021201677A1 (en) | 2020-04-01 | 2021-10-07 | Kiadis Pharma Intellectual Property B.V. | Compositions and methods targeting influenza |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6103243A (en) * | 1985-05-15 | 2000-08-15 | Biotechnology Australia Pty, Ltd | Oral vaccines |
US5811128A (en) * | 1986-10-24 | 1998-09-22 | Southern Research Institute | Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor |
US5332567A (en) * | 1989-08-24 | 1994-07-26 | Immunomedics | Detection and treatment of infections with immunoconjugates |
US5290686A (en) * | 1991-07-31 | 1994-03-01 | The United States Of America As Represented By The Department Of Health And Human Services | Expression of influenza a M2 protein in baculovirus |
US5240694A (en) * | 1991-09-23 | 1993-08-31 | University Of Virginia | Combined antiviral and antimediator treatment of common colds |
US5686078A (en) * | 1992-09-14 | 1997-11-11 | Connaught Laboratories, Inc. | Primary and secondary immunization with different physio-chemical forms of antigen |
US5928647A (en) * | 1993-01-11 | 1999-07-27 | Dana-Farber Cancer Institute | Inducing cytotoxic T lymphocyte responses |
EP0680337A4 (en) * | 1993-01-12 | 1997-07-30 | Anthony George Gristina | METHODS AND COMPOSITIONS FOR DIRECT APPLICATION WITH HIGH CONCENTRATION OF ANTIBODIES, PRODUCING PASSIVE IMMUNITY. |
JP2996864B2 (ja) * | 1994-03-30 | 2000-01-11 | 寳酒造株式会社 | 抗体可変領域dna |
US6096291A (en) * | 1996-12-27 | 2000-08-01 | Biovector Therapeutics, S.A. | Mucosal administration of substances to mammals |
DK0996717T3 (da) * | 1997-08-05 | 2006-04-10 | Vlaams Interuniv Inst Biotech | Immunbeskyttende influenzaantigen og anvendelse deraf til vaccination |
US6169175B1 (en) * | 1997-08-06 | 2001-01-02 | Centers For Disease Control And Prevention | Preparation and use of recombinant influenza A virus M2 construct vaccines |
WO2000032626A1 (en) * | 1998-11-25 | 2000-06-08 | Regents Of The University Of Minnesota | Methods of using epitope peptides of human pathogens |
DE60043708D1 (de) * | 1999-10-13 | 2010-03-04 | Novartis Vaccines & Diagnostic | Verfahren zur erhaltung zellimmuneantworten gegen proteinen |
-
2003
- 2003-03-13 CN CNA03810797XA patent/CN1652815A/zh active Pending
- 2003-03-13 CA CA002478973A patent/CA2478973A1/en not_active Abandoned
- 2003-03-13 JP JP2003576594A patent/JP2005519619A/ja active Pending
- 2003-03-13 KR KR10-2004-7014352A patent/KR20040111402A/ko not_active Application Discontinuation
- 2003-03-13 EP EP03719398A patent/EP1490099A4/en not_active Withdrawn
- 2003-03-13 TW TW092105484A patent/TW200407161A/zh unknown
- 2003-03-13 US US10/389,221 patent/US20030219442A1/en not_active Abandoned
- 2003-03-13 AU AU2003223285A patent/AU2003223285A1/en not_active Abandoned
- 2003-03-13 WO PCT/US2003/008147 patent/WO2003078600A2/en active Application Filing
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102238963A (zh) * | 2008-12-04 | 2011-11-09 | 英特塞尔股份公司 | 完全人源性流感m2特异性抗体 |
CN101881770A (zh) * | 2009-05-08 | 2010-11-10 | 青岛农业大学 | 猪圆环病毒2型胶体金抗体快速检测试纸条的制备方法 |
CN101881770B (zh) * | 2009-05-08 | 2013-07-10 | 青岛农业大学 | 猪圆环病毒2型胶体金抗体快速检测试纸条的制备方法 |
CN106715700A (zh) * | 2014-01-10 | 2017-05-24 | 艾乐美生物科技有限公司 | 能产生比小鼠IgE量高出许多的人源化IgE的基因转殖动物 |
CN105934443A (zh) * | 2014-01-27 | 2016-09-07 | 豪夫迈·罗氏有限公司 | 抗h7病毒抗体治疗h7n9流感 |
CN112961237A (zh) * | 2021-03-10 | 2021-06-15 | 中国计量科学研究院 | 人源化IgM单克隆抗体标准物质及制备方法 |
Also Published As
Publication number | Publication date |
---|---|
WO2003078600A2 (en) | 2003-09-25 |
EP1490099A2 (en) | 2004-12-29 |
JP2005519619A (ja) | 2005-07-07 |
EP1490099A4 (en) | 2006-02-08 |
AU2003223285A8 (en) | 2003-09-29 |
KR20040111402A (ko) | 2004-12-31 |
AU2003223285A1 (en) | 2003-09-29 |
CA2478973A1 (en) | 2003-09-25 |
US20030219442A1 (en) | 2003-11-27 |
WO2003078600A3 (en) | 2004-07-01 |
TW200407161A (en) | 2004-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1652815A (zh) | 针对流感病毒m2蛋白的人单克隆抗体其制备和使用方法 | |
CN1237076C (zh) | 具有改变的效应功能的多肽变体 | |
CN1187374C (zh) | 人源化的特异于人4-1bb的抗体和含有它的药物组合物 | |
EP3638698A1 (en) | Anti-tmprss2 antibodies and antigen-binding fragments | |
CN1413220A (zh) | 抗前列腺干细胞抗原(psca)抗体组合物及其应用方法 | |
CN1886426A (zh) | 结合白细胞介素-4受体的抗体 | |
CN1492040A (zh) | 单克隆人天然抗体 | |
CN1268645C (zh) | 含有抗-fc受体结合剂的治疗化合物 | |
CN1889979A (zh) | Ip-10抗体及其用途 | |
CN101074261A (zh) | Trail受体1和/或trail受体2特异性抗体及其应用 | |
CN1902231A (zh) | 具有增加的Fc受体结合亲和性和效应子功能的CD20抗体 | |
CN1558916A (zh) | 产生嵌合异源多聚体的组合物和方法 | |
CN100339395C (zh) | 戊型肝炎病毒单克隆抗体及其用途 | |
CN1656122A (zh) | 人源抗白细胞介素5单克隆抗体及其制备方法和包含这些抗体的组合物 | |
CN1602317A (zh) | 血管生成素-2的特异结合剂 | |
CN1738646A (zh) | 可用来抵御并治疗hiv感染的去免疫化单克隆抗体 | |
CN1809592A (zh) | 识别n-乙醇酰gm3神经节苷脂的重组抗体和片段以及其在肿瘤诊断和治疗上的应用 | |
CN101072795A (zh) | 针对流感病毒m2蛋白的人单克隆抗体及其制备和使用方法 | |
CN1852981A (zh) | 抗血小板膜糖蛋白vi单克隆抗体 | |
CN1856508A (zh) | 针对HCV E2糖蛋白并赋予了体外中和活性的人单克隆抗体Fab片段 | |
CN1551783A (zh) | 治疗多发性骨髓瘤的方法 | |
Paudyal et al. | Fc-mediated functions of porcine IgG subclasses | |
CN1283662C (zh) | 拮抗性抗hFAS配基人类抗体及其片段 | |
CN1531554A (zh) | 血纤维蛋白d-二聚体片段特异性的、来源于dd-3b6/22的人源化抗体 | |
CN101039955A (zh) | 与sars冠状病毒刺突蛋白相关的核酸、多肽、表达方法和免疫原性组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1081439 Country of ref document: HK |
|
ASS | Succession or assignment of patent right |
Owner name: KIRIN MEDICINE CO., LTD.; APPLICANT Free format text: FORMER OWNER: QILIN CO., LTD.; APPLICANT Effective date: 20080718 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20080718 Address after: Tokyo, Japan Applicant after: Kirin Pharmaceutical Co., Ltd. Co-applicant after: La Jolla Institute For Allergy and Immunology Address before: Tokyo, Japan Applicant before: Kirin Holdings Co-applicant before: La Jolla Institute For Allergy and Immunology |
|
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |
Open date: 20050810 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1081439 Country of ref document: HK |